Introduction
Early diagnosis, followed by early initiation and optimal adjustments of aggressive therapies, are acknowledged as essential to optimize long-term clinical and radiologic outcome in rheumatoid arthritis (RA) [1] [2] [3] [4] [5] . This requires sensitive methods for detection and monitoring of the disease process. Particularly during the early phase of the disease, however, the conventional methods such as clinical examination, laboratory tests, and radiography are neither sensitive nor specific, and do not allow detailed evaluation of synovial inflammation or early cartilage or bone destruction [6] [7] [8] .
During the last decade, an increasing number of studies have reported a superiority of ultrasonography (US) to conventional methods for evaluation of RA joints. This conclusion has mainly been based on the visualization of inflammatory and/or destructive joint changes that were not detected by clinical and radiographic examinations [9] [10] [11] [12] [13] [14] [15] [16] [17] .
Given this encouraging information, plus the attraction of quick, inexpensive, and easily accessible assessment of RA and suspected RA patients, and the resulting expected future role as an outcome measure in RA, it is highly relevant to consider the validity of US measures of rheumatoid joint inflammation and damage as we ask the question: Do we currently have enough knowledge to conclude that US measures are valid indicators for joint inflammation and destruction in RA and suspected RA?
Validity assessment involves various aspects (Table 1 [18•]) [19] . Preceded by a description of the current status of US in RA, this paper, organized by type of validity and emphasizing recent achievements, reviews available data and discusses research priorities of US in suspected, early, and established RA. The small joints of the hands and feet are the joints earliest and most frequently involved in RA, and data from these joints are the main focus of this review.
Ultrasonography in rheumatoid arthritis: current status
Recent technologic advances have made US a very promising tool for assessment of RA patients. Although acceptable ultrasonographic assessment was previously confined to large joints [11] [12] [13] 20 ,21], high-frequency (10 to 22-MHz) transducers now allow high-resolution imaging of superficially located structures as the joints of hands and feet [9, [14] [15] [16] [17] 22 A sensitivity of ultrasound for visualizing bone erosions in the finger joints higher than radiography and comparable with MRI has been documented [15, 16, 52] . Preliminary data suggest similar findings in the metatarsophalangeal joints ( Figure 2) [53, 54] .
The cartilage can be visualized with US, but because ultrasound cannot penetrate bone, many joint surfaces are inaccessible to US, particularly in anatomically complicated joints [14, 55] . Systematic studies of the cartilage in RA finger joint cartilage have not been performed [10, 56] .
Advantages of US include its noninvasiveness, relative inexpensiveness, lack of ionizing radiation, ability to visualize both inflammatory and destructive disease manifestations, and easy repeatability, making it potentially useful for frequent patient follow-up [57] . Furthermore, US can be used to guide punctures of joints, bursae, and tendon sheaths [14, [58] [59] [60] [61] , with ensuing improved success rates of diagnostic or therapeutic aspirations and injections [61] [62] [63] . A particular advantage is the potential to be a routine tool used by the rheumatologists in the outpatient clinics, as the "extended hand of the rheumatologist" [57, 58, 64] .
The disadvantages of US include its dependency on the presence of a skilled operator, and poor objective documentation of findings. Potential problems with reproducibility, based on variation between results obtained by different observers and/or by different equipment, are also often mentioned [65] . However, recent studies have found good interobserver agreement on assessment of key features of hand and foot joint RA, synovitis, and bone erosions [30,66•].
Considering its use in routine management, the fact that the presence of a trained physician implies costs, use of hospital resources (eg, extra minutes in the outpatient clinic), and potential physician availability problems should also be remembered. However, if US provides quick, accurate answers, leading to prompt, therapeutic consequences without needing to wait for further examinations, this will undoubtedly outweigh the disadvantages.
The need for standardization of methods, generally accepted strict and explicit definitions of pathologies, and validation of evaluation methods through comparisons with gold standards, reproducibility assessments, and well-designed follow-up studies are addressed in detail in the following paragraphs. 
Face and content validity: credibility and comprehensiveness
Face validity is credibility (ie, whether a measure appears to measure what it is supposed to), whereas content validity is comprehensiveness (ie, whether a measure covers all aspects of the attribute to be measured). Face and content validities are essentially subjective.
US provides direct visualization and assessment of synovitis, the primary site of disease in RA, with good image quality and spatial resolution, and it has the potential to evaluate several features of the synovium, such as the thickness, blood flow, and, with new three-dimensional software, potentially volume [18•,23•,36,39], and of other features of importance such as tendons, tendon sheaths, joint fluid accumulations, and, at accessible sites, cartilage and bone erosions [15, 25, 30] . However, because ultrasound cannot penetrate bone, intraosseous pathologies (eg, bone edema) and bone erosions at many locations, particularly in complex joints, cannot be detected.
US allows assessment of multiple joints during one session, and, even though feasibility issues (time requirements) must be considered, examination of a representative extract of the patient's joints is possible. Thus, US measures of joint inflammation and to some extent of destructive joint damage in RA, must be considered to have face and content validity (Table 1 ).
Criterion validity: agreement with concurrent and future gold standards
Criterion validity is the degree to which a measure truly reflects a "gold standard." There are two types of criterion validity: concurrent validity (ie, the degree to which a measure reflects a gold standard applied at the same time [eg, pathologic evidence of joint inflammation and destruction] and predictive validity, which is the degree to which a measure predicts a future gold standard outcome (eg, radiographic status or functional impairment).
Concurrent validity
For US measures of synovitis, the most convincing comparator or gold standard is microscopic or macroscopic pathologic evidence of synovial inflammation. Walther et al. [21, 67•] have found a close correlation between histologic vascularity and visual grades of power Doppler signal in the synovium in knee joints (RA/osteoarthritis patients, 10 of 13; Spearman = 0.89, P < 0.01) and, recently, also in hip joints (RA/osteoarthritis patients, 9 of 15; = 0.92, P < 0.01) in patients undergoing arthroplasty. In agreement with this, Schmidt et al. [ In summary, some comparisons with pathology as gold standard exists for US measures of synovitis, but not in the small joints and not for US of bone damage, in which MRI constitutes the best published reference method. More data are desirable, especially in early small-joint disease, but histopathologic verification from finger joints of these patients is not easily achievable.
Predictive validity
No data on the importance of US findings with respect to later radiographic or functional status are available (ie, the prognostic value of US in RA is unknown). Some indirect support of a predictive value of US is provided by the high agreement with MRI findings [15,22•,23•,39•,52], because MRI findings (synovitis, bone edema, and MRI bone erosions) have been shown to possess predictive value with respect to subsequent destructive bone damage both within the next 1 year [76-79] and within the next 5 to 6 years [80•,81]. In several studies, however, the strongest MRI predictor of future erosive damage was the presence of bone marrow edema [76,79,80•], which cannot be visualized by US. Consequently, the prognostic value of MRI is not directly transferable to US. In conclusion, a prognostic value of US findings in RA is so far undocumented. Systematic studies of this are needed.
Construct validity
Construct validity is consistency with theoretic concepts (eg, that a US measure of synovitis is related to other measures of synovitis). In accordance with the expectations of markers of synovial inflammation exposed to effective antiinflammatory drugs, US measures of synovitis (US Doppler signal and B-mode synovial membrane thickness) decrease when glucocorticoids [13, 40, 41] follow-up study of bone erosions on US, the number of erosions increased over time, in agreement with the general view that erosive damage progresses over time in most RA patients.
Discriminant validity: sensitivity to change
Discriminant validity means that the measure can detect clinically important degrees of change. Both a variation in the measure over time (eg, treatment induced) and a sufficient reproducibility to allow a reliable detection of this change are required.
Reproducibility
A prerequisite for sensitivity to change is that the measure is reproducible. Hitherto, US studies in RA have used joint pathology definitions, scanning techniques, and evaluation/scoring systems developed within the individual research centers. No consensus exists, making comparison of study results difficult. Furthermore, the intra-and interobserver variations of the used measures have only been tested in a minority of studies [16,18•, 23•,66•,82], whereas the interscanner variation remains untested.
Recently, advances in this area were made. Backhaus et al. [57] in an EULAR working group have provided guidelines for musculoskeletal US in rheumatology, addressing technical issues, training, and standardization of image acquisitions, but not evaluation methods. A US self-training approach has been described [83]. Wakefield et al. [16] proposed a definition and a scoring system for erosions, and reported good intraobserver agreement rates when using it. Ribbens et al. [18•] described the reproducibility and sensitivity to change (described in the next paragraph) of several measures of synovitis, whereas others in a series of studies have suggested definitions of important joint pathologies (assessed by grayscale and power Doppler US), and a corresponding scoring system for hands and feet, on which available validation data so far include high agreement rates between observers and with MRI [23•,31,46,54,66•]. Unfortunately, no longitudinal data are yet available, and the system has not been tested by other groups, precluding final conclusions on its usefulness [84] . An OMERACT working group on US in RA has recently been formed, with the aim to address validity issues, hopefully leading to a higher degree of international consensus on techniques, joint pathology definitions, and scoring systems for use of US in RA.
Sensitivity to change
The repeatability index (two standard deviations of the differences between repeated measurements) is useful to determine the smallest difference between two values of a measure that can be reliably detected (smallest detectable difference) [85, 86] . Only one US study involving RA small joints (wrist, finger and/or toe joints) included both reproducibility and longitudinal data [18•].
In this study by Ribbens et al. [18•] , intra-and interobserver variations on grayscale US determined synovial membrane thicknesses in wrist, metacarpophalangeal, and proximal interphalangeal joints of 11 RA patients were assessed, with intraobserver coefficients of variation of 1.9 to 2.6% and interobserver coefficients of variation of 10.2 to 11.0%. The smallest detectable difference was not determined, but infliximab therapy changed the synovial thickness more than the coefficient of variation in most joints, suggesting that this measure is sensitive to change in clinically relevant situations [18•].
To our knowledge, the course of US bone erosions have only been followed systematically by Backhaus et al.
[22•]. In 49 patients with various arthritides, MRI, US, and radiography of wrist, metacarpophalangeal, and proximal interphalangeal joints were analyzed at baseline and after 2 years. MRI and US signs of synovitis decreased, whereas the number of bone erosions on MRI and US increased. More patients showed erosive progression on US compared with radiography, suggesting a higher sensitivity to change. However, because the reproducibility was not evaluated, it is not known whether the erosive progression noted exceeded the variation that could be caused by measurement error (ie, how frequently the progression registered exceeded the smallest detectable difference). In conclusion, very few studies have looked at the sensitivity to change of US measures of synovitis and, particularly, destructive damage in RA small joints.
Diagnostic value
Although manuscript titles may occasionally suggest so, no studies have truly investigated the diagnostic value of US in RA, because the ability of US to distinguish between RA patients and other relevant differential diagnoses has not been tested.
A few studies have described differences in findings among different arthritides. A study by Frediani et al.
[29] suggested, in agreement with comparable MRI studies [27, 87, 88] , that in RA, US signs of inflammation are more frequent in the joint than at the tendon insertions (enthesitis), whereas the opposite is true for psoriatic arthritis. In accordance with this, other studies report that US signs of peripheral enthesitis are frequent in seronegative spondyloarthropathies [30•,82], but not in RA [30•].
It would be expected that the ability of US to visualize intra-as well extraarticular changes would translate into that US could in some cases assist in the clinical process of diagnosing a specific rheumatologic condition, but this is not scientifically verified. Current knowledge strongly encourages testing this hypothesis, particularly in patients with early, unclassified arthritis.
Future research priorities
US is a very promising method for assessment of RA patients, but a number of issues still need to be systematically studied. Suggested areas of priority in research and development of US in RA are listed below, and subsequently discussed in more detail: International efforts on standardization of methods and development of generally accepted strict and explicit definitions of pathologies are essential. It is equally important to validate existing evaluation methods and, if these are not sufficient, to develop, reiteratively test, improve, and finally internationally agree on new scoring methods and/or relevant qualitative or quantitative methods. Furthermore, the very limited knowledge on intraobserver, interobserver, and particularly interscanner variation should be extended.
Cross-sectional studies with comparisons with reliable gold standards (eg, histopathology for synovitis/tenosynovitis and CT/cadavers for bone erosions) are desirable. Cross-validation with MRI findings is also valuable.
Longitudinal studies comparing the prognostic value of US findings compared with other candidate prognostic factors, are essential to test the criterion validity and, consequently, to clarify the true potential of US in RA.
Longitudinal studies, looking at sensitivities to change US measures of inflammation and destruction, by com-paring therapy-induced changes with reproducibility, are urgently needed. By such studies, the potential as outcome measures in RA clinical trials, but also as a tool in the routine clinical management of RA patients, can be determined.
The value of US in the diagnosis of RA is unknown and should be studied. It should be tested to which extent certain characteristic US findings in unclassified disease enables differentiation between different disease entities (eg, by studying patients with suspected early inflammatory joint disease), with the long-term follow-up diagnosis as the gold standard reference.
Because US is increasingly used by rheumatologists, it is of interest to define certain quality standards and to explore how much education and training rheumatologists need to fulfill these standards.
US undergoes continuous technical improvements, and the benefit of these advances in RA imaging should obviously be continuously investigated. Such research includes addressing the benefits of existing and new US contrast agents, and of novel ultrasound equipment (eg, with higher frequency transducers, improved flow sensitivities, tissue harmonic imaging, and/or in other ways improved grayscale imaging). Quantitative measures obtainable by spectral Doppler (ie, resistive and pulsatility indices and color pixel fraction) appear potentially useful [39•], but their reproducibility is unknown and needs clarification, before conclusions on their value in RA can be made.
Novel, true three-dimensional options, recording threedimensional data tracked by a magnetic sensor, are now available on some high-end machines. Besides making quantitative assessments of tissues of interest a possibility, the technique may reduce the problems with documentation and centralized readings, which have so far minimized the potential of US in clinical trials.
Finally, US is also potentially very useful for diagnosis and assessment of other inflammatory joint diseases, (eg, the spondyloarthropathies). It is of high interest also in these diseases to study all the issues mentioned earlier.
Conclusion
There is increasing evidence of the ability of US to detect and monitor inflammatory and destructive disease manifestations in RA joints. Because US is also a relatively inexpensive, accessible, and patient-friendly method, US is likely to become a routinely used bedside tool for improved joint assessments and injections by the rheumatologists. This is already the case in some European countries. However, the validation data on US in RA are incomplete, and a number of issues needs to be clarified before the value of US in diagnosis, monitoring, and prognostication of patients with established, early, and suspected RA is clarified.
